Secukinumab biosimilar for treating plaque psoriasis

Secukinumab biosimilar is in clinical development for the treatment of moderate to severe plaque psoriasis in adults. Plaque psoriasis is a long-lasting autoimmune disease that causes skin cells to reproduce very quickly. Plaque psoriasis is characterised by thick, scaly patches called plaques on the skin. These plaques most commonly effect elbows, the back, knees, and scalp. In more severe cases, plaques can appear on the entire body including the face, feet, and genitals. Plaque psoriasis is most common in people that are white, drink alcohol, live stressful lifestyles, experience depression, are obese and who smoke tobacco. Biosimilar medicines are biological therapies which have no clinically meaningful differences in efficacy, quality, and safety compared to the reference biologic product. Biosimilars are competitively priced to compete with the original medicinal product allowing them to be more widely available to the patients who need them.